10 / 10
Page 35
Notes:
J Pharmacol Ther Res 2017 Volume 1 Issue 2
allied
academies
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
N
anoemulsions (NE) are oil-in-water emulsions containing
high energy nanometer-sized droplets stabilized by
surfactants, and specifically designed for topical and mucosal
targeted delivery. Due to their size (less than 500nm) and
surface-active properties they to traverse the skin via pores,
hair follicles, and mucosal membranes, but are excluded from
entering the tight junctions of the epithelium. As a result,
they can be highly bioavailable in the tissues, without causing
disruption of the normal epithelial matrix. Nanoemulsions can
delivery agents across the nasal mucosa for the desired clinical
(therapeutic) effect. We have testing these formulation in high-
throughput screens and found NE induced immunogenicity
and antigen delivery are facilitated through initial contact
interactions between the NE droplet and mucosal surfaces,
which promote prolonged residence of the vaccine at the site
of application, and thus cellular uptake. We have incorporated
small molecule, peptides/proteins and large macromolecules
in optimized nanoemulsion formulation for transmucosal
delivery. Nanoemulsions can delivery agents across the nasal
mucosa for therapeutic effects. Nanoemulsions delivered
topically are inherently antimicrobial and lyse pathogens upon
contact, thereby overcoming existing resistance mechanisms.
Other anti-microbial, anti-fungal and anti-viral agents can be
entrapped inside thenanoemulsion andenhanceddrug delivery
of these agents. Studies of a novel nanoemulsion formulated
with other agents demonstrates significantly higher levels are
achieved as compared to commercially available products.
Recently discovered, a topical nanoemulsion therapy acting as a
topical antimicrobial was found to halt burn wound progression
in a swine burn wound model. The nanoemulsion reduced the
bacterial growth in the burn wound tominimal levels compared
to saline and silver sulfadiazine and significantly reduced
levels of dermal inflammatory cytokines. By reducing excess
influx of neutrophils into the burn wound and modulating the
pro-inflammatory response, the nanoemulsion formulations
attenuated burn wound progression in the early post-injury
phase and prevented conversion of burn wounds from partial
thickness to full thickness. This discovery, if demonstrated in
man, would lessen the need for skin grafting, speed recovery,
result in fewer infectious complications, and improve the
outcomes by preventing the conversion to full thickness
wounds. Among its many uses nanoemulsion therapy is a
potential new breakthrough treatment for preventing burn
wound progression.
Speaker Biography
Susan Ciotti, PhD is the Director of Formulations at NanoBio Corporation, where
she directs the nanoemulsion adjuvant formulation efforts. She is responsible for
developing novel nanoemulsion formulations, nanoemulsion manufacturing (process
optimization/scale-up) and clinical trial materials for the vaccine clinical trials. Her
career has focused on principally on developing nanotechnology formulations. During
her tenure at Johnson and Johnson, she spearheaded several projects related to
developing formulations for the treatment of topical and nasal preparation, as well
as sterile parental formulation. She has served as the lead for several projects at
various stages of dermatological, parenteral and biological drug product development.
She is currently leading NanoBio’s formulation efforts on a NIAID contract entitled
“Next Generation Anthrax Vaccine”. She was the co-investigator on Nanoemulsion-
based antimicrobials for the protection against burn and wound infection funded by
the U.S. Army Medical Research and Material Command (USAMRC, Award Number:
W81XWH-11-2-005). Dr Ciotti received her graduate degrees in Pharmaceutical
Sciences from the University of Michigan, Ann Arbor, MI. She is a Professor of
Pharmaceutical Sciences at the College of Pharmacy where she teaches novel drug
delivery and nanotechnology to graduate students.
e:
susan.ciotti@nanobio.comSusan Ciotti
NanoBio Corporation, USA
Nanoemulsion-Based therapies: Antimicrobial, anti-inflammatory and drug delivery
properties